Signal TrailDeveloping
CAR-T Is Escaping Its Original Box
Across leukemia, lupus, kidney transplant desensitization, and solid tumor approval, CAR-T is showing up as a broader platform, not just a blood-cancer treatment.
Why now
Several CAR-T stories are clustering at once across patient care, autoimmune disease, transplant access, and solid-tumor approval.
- Overclaim risk
- medium-high
- Primary source
- Official
- Published
- Jun 25, 2026
Read brief ->
